Last reviewed · How we verify
Calaspargase pegol-mknl
Calaspargase pegol-mknl is a pegylated asparaginase that depletes asparagine, an amino acid required for leukemic cell survival and proliferation.
Calaspargase pegol-mknl is a pegylated asparaginase that depletes asparagine, an amino acid required for leukemic cell survival and proliferation. Used for Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy.
At a glance
| Generic name | Calaspargase pegol-mknl |
|---|---|
| Also known as | Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol, EZN-2285, SC-PEG E. Coli L-Asparaginase |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Asparaginase (pegylated) |
| Target | Asparagine (amino acid depletion) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug is a modified form of asparaginase conjugated to polyethylene glycol (PEG), which reduces asparagine levels in the bloodstream. Leukemic cells, particularly in acute lymphoblastic leukemia (ALL), depend on exogenous asparagine for protein synthesis and cannot synthesize it endogenously, making them sensitive to asparagine depletion. The pegylation extends the drug's half-life and reduces immunogenicity compared to native asparaginase.
Approved indications
- Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy
Common side effects
- Hypersensitivity reactions
- Pancreatitis
- Hepatotoxicity
- Coagulopathy
- Hyperglycemia
- Nausea and vomiting
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) (PHASE2)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calaspargase pegol-mknl CI brief — competitive landscape report
- Calaspargase pegol-mknl updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI